These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling. Zhang X; Qin T; Zhu Z; Hong F; Xu Y; Zhang X; Xu X; Ma A Am J Med Sci; 2020 Feb; 359(2):123-129. PubMed ID: 32039764 [TBL] [Abstract][Full Text] [Related]
23. Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR. Chien W; Tyner JW; Gery S; Zheng Y; Li LY; Gopinatha Pillai MS; Nam C; Bhowmick NA; Lin DC; Koeffler HP J Ovarian Res; 2023 Apr; 16(1):80. PubMed ID: 37087441 [TBL] [Abstract][Full Text] [Related]
25. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues. Gan M; Tai Z; Yu Y; Zhang C; Xu J PeerJ; 2023; 11():e14653. PubMed ID: 36721777 [TBL] [Abstract][Full Text] [Related]
26. CACNA1H restrains chemotherapy resistance in ovarian clear cell carcinoma cells by repressing autophagy. Shi H; Zheng L; Jiang X; Chen H Mol Genet Genomics; 2024 Aug; 299(1):77. PubMed ID: 39105964 [TBL] [Abstract][Full Text] [Related]
27. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. Wang JY; Chang CC; Chiang CC; Chen WM; Hung SC J Cell Biochem; 2012 May; 113(5):1733-43. PubMed ID: 22213051 [TBL] [Abstract][Full Text] [Related]
29. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863 [TBL] [Abstract][Full Text] [Related]
30. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032 [TBL] [Abstract][Full Text] [Related]
31. EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-X Inoue-Yamauchi A; Oda H Biochem Biophys Res Commun; 2020 Jun; 526(3):612-617. PubMed ID: 32247610 [TBL] [Abstract][Full Text] [Related]
32. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma. Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703 [TBL] [Abstract][Full Text] [Related]
33. Restoration of ARID1A Protein in ARID1A-deficient Clear Cell Carcinoma of the Ovary Attenuates Reactivity to Cytotoxic T Lymphocytes. Tsunematsu R; Murai A; Mizue Y; Kubo T; Mariya T; Morita R; Murata K; Kanaseki T; Tsukahara T; Hirohashi Y; Saito T; Torigoe T Cancer Genomics Proteomics; 2024; 21(4):414-420. PubMed ID: 38944423 [TBL] [Abstract][Full Text] [Related]
34. Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma. Mehner C; Miller E; Hockla A; Coban M; Weroha SJ; Radisky DC; Radisky ES Oncogene; 2020 Oct; 39(42):6606-6618. PubMed ID: 32929152 [TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003 [TBL] [Abstract][Full Text] [Related]
36. OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway. Liu L; Liang C; Zhuo C; Jiang H; Ye H; Ruan T; Song J; Jiang S; Zhang Y; Li X Med Oncol; 2022 Jan; 39(2):26. PubMed ID: 34982265 [TBL] [Abstract][Full Text] [Related]
37. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations. Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027 [TBL] [Abstract][Full Text] [Related]
39. Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report. Farah AM; Gu S; Jia Y Medicine (Baltimore); 2022 Sep; 101(37):e30666. PubMed ID: 36123851 [TBL] [Abstract][Full Text] [Related]
40. Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun. Itamochi H; Oishi T; Shimada M; Sato S; Uegaki K; Naniwa J; Sato S; Nonaka M; Terakawa N; Kigawa J; Harada T Clin Cancer Res; 2011 Jul; 17(14):4742-50. PubMed ID: 21610153 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]